FrancophonIA/ELRC3.0 huggingface dataset:
English: coagulation factor VIII 500 IU von Willebrand factor 1200 IU
Croatian: faktor zgrušavanja VIII 500 IU von Willebrandov faktor 1200 IU
English: Posology von Willebrand disease
Croatian: Doziranje von Willebrandova bolest
English: Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusionhuman coagulation factor VIII/human von Willebrand factor
Croatian: Voncento 1000 IU FVIII / 2400 IU VWF (10 ml otapala) prašak i otapalo za otopinu za injekciju/infuziju ljudski koagulacijski faktor VIII/ljudski von Willebrandov faktor
English: Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion human coagulation factor VIII/human von Willebrand factor
Croatian: Voncento 250 IU FVIII / 600 IU VWF(5ml otapala) prašak i otapalo za otopinu za injekciju/infuziju ljudski koagulacijski faktor VIII/ljudski von Willebrandov faktor
English: Voncento 250 IU FVIII / 600 IU VWF powder for solution for injection/infusion For IV use
Croatian: Voncento 250 IU FVIII / 600 IU VWF prašak za otopinu za injekciju/infuziju Za i.v. primjenu
English: The presentations 250 IU FVIII /600 IU VWF (5 ml solvent) and 500 IU FVIII /1200 IU VWF (5 ml solvent) contain up to 14.75 mg sodium per vial (main component of cooking/table salt).
Croatian: Pakiranja 250 IU FVIII /600 IU VWF (5 ml otapala) i 500 IU FVIII / 1200 IU VWF (5 ml otapala)
English: CSL Behring AB Puh/Tel: +46 8 544 966 70
Croatian: Suomi/Finland CSL Behring AB Puh/Tel: +46 8 544 966 70
English: Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusionhuman coagulation factor VIII/human von Willebrand factor
Croatian: Voncento 500 IU FVIII /1200 IU VWF (5 ml otapala) prašak i otapalo za otopinu za injekciju/infuziju ljudski koagulacijski faktor VIII/ljudski von Willebrandov faktor
English: Voncento 500 IU FVIII / 1200 IU VWF(10 ml solvent) powder and solvent for solution for injection/infusion human coagulation factor VIII/human von Willebrand factor
Croatian: Voncento 500 IU FVIII / 1200 IU VWF (10 ml otapala) prašak i otapalo za otopinu za injekciju/infuziju ljudski koagulacijski faktor VIII/ljudski von Willebrandov faktor
English: Prophylaxis treatment
Croatian: Farmakokinetika
English: • you notice any symptoms of an impaired perfusion in your extremities (e.g. cold and pale extremities) or vital organs (e.g. severe chest pain)
Croatian: • primijetite bilo kakve simptome oslabljenog protoka krvi u udovima (na primjer hladne i blijede ruke i noge) ili vitalnim ogranima (npr. jaka bol u prsnom košu) Postoji i rizik od nastanka krvnih ugrušaka (tromboza), posebice u bolesnika s poznatim čimbenicima rizika (vidjeti također dio 2.) Sljedeće nuspojave opažene su vrlo često (mogu se javiti u više od 1 na 10 osoba):
English: Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion
Croatian: Voncento 250 IU FVIII / 600 IU VWF prašak i otapalo za otopinu za injekciju/infuziju
English: Other medicines and Voncento
Croatian: Izvlačenje lijeka i primjena
English: Paediatric haemophilia A population
Croatian: Pedijatrijska populacija s hemofilijom A
English: Voncento 500 IU FVIII / 1200 IU VWF powder for solution for injection/infusion For IV use
Croatian: Voncento 500 IU FVIII / 1200 IU VWF prašak za otopinu za injekciju/infuziju Za i.v. primjenu
English: Voncento 500 IU FVIII /1200 IU VWF powder for solution for injection/infusion For IV use
Croatian: Voncento 500 IU FVIII /1200 IU VWF prašak za otopinu za injekciju/infuziju Za i.v. primjenu
English: Voncento 250 IU FVIII / 600 IU VWF powder and solvent for solution for injection/infusion Powder (250 IU/600 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Croatian: Prašak (250 IU/600 IU) u bočici (staklo tipa I), s čepom (guma), diskom (plastika) i zatvaračem
English: Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion
Croatian: Voncento 500 IU FVIII / 1200 IU VWF prašak i otapalo za otopinu za injekciju/infuziju
English: After reconstitution with the 5 ml water for injections provided, the solution contains 100 IU/ml of FVIII and 240 IU/ml of VWF.
Croatian: Nakon rekonstitucije s 5 ml vode za injekcije koja je priložena, otopina sadrži 100 IU/ml FVIII i 240
English: Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion
Croatian: 1 nesterilni flaster Voncento 1000 IU FVIII / 2400 IU VWF prašak i otapalo za otopinu za injekciju/infuziju
English: 1 disposable 10 ml syringe
Croatian: 1 bočica s 5 ml vode za injekcije
English: Voncento 500 IU FVIII / 1200 IU VWF powder and solvent for solution for injection/infusion Powder (500 IU/1200 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Croatian: Prašak (500 IU/1200 IU) u bočici (staklo tipa I), s čepom (guma), diskom (plastika) i zatvaračem
English: Voncento 1000 IU FVIII / 2400 IU VWF powder and solvent for solution for injection/infusion Powder (1000 IU/2400 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Croatian: Prašak (1000 IU/1200IU) u bočici (staklo tipa I), s čepom (guma), diskom (plastika) i zatvaračem
English: --1 Per 1 ml dose: purified p45 FeLV-envelope antigen, minimum quantity 102 µg
Croatian: --1 Po dozi 1 ml: najmanja količina pročišćenog antigena omotača p45 FeLV 102 µg
English: EU (MA) number Invente d name
Croatian: Izmišljeno ime
English: This summary was last updated in 08-2014.
Croatian: Ovaj sažetak je posljednji put ažuriran u 08.2014.
English: Lyxumia is injected once a day, in the hour before the same meal every day.
Croatian: Lyxumia se injektira jednom na dan u satu prije istog obroka svaki dan.
English: The full EPAR for Lyxumia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku Lyxumia (EPAR) može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Allergic reactions have been reported in less than 1 in 100 patients using Lyxumia.
Croatian: Alergijske reakcije prijavljene su kod manje od 1 na 100 bolesnika koji su koristili lijek Lyxumia.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lyxumia on 1 February 2013.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Lyxumia na snazi u Europskoj uniji od 1. veljače 2013.
English: Adding Lyxumia to metformin is not associated with this risk.
Croatian: Dodavanje lijeka Lyxumia metforminu nije povezano s ovim rizikom.
English: These side effects were mostly mild and usually resolved over time.
Croatian: Te su nuspojave najčešće bile blage i obično su se povukle s vremenom.
English: This is a summary of the European public assessment report (EPAR) for Lyxumia.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Lyxumia.
English: What measures are being taken to ensure the safe and effective use of Lyxumia?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lyxumia?
English: It is available as a solution for injection in a pre-filled pen that provides either 10 micrograms or 20 micrograms of lixisenatide in each dose.
Croatian: Dostupan je kao otopina za injekciju u napunjenoj štrcaljki koja isporučuje 10 mikrograma ili 20 mikrograma liksisenatida u svakoj dozi.
English: Lyxumia has been studied in seven main studies involving 3,825 adults with type 2 diabetes.
Croatian: Lyxumia je ispitivana u sedam glavnih ispitivanja koja su uključivala 3 825 odraslih bolesnika s dijabetesom tipa 2.
English: Lyxumia lixisenatide
Croatian: Lyxumia liksisenatid
English: Other information about Lyxumia
Croatian: Ostale informacije o lijeku Lyxumia
English: When Lyxumia is injected, lixisenatide reaches the receptors in the pancreas and activates them.
Croatian: Kad se Lyxumia injektira liksisenatid doseže receptore u gušterači i aktivira ih.
English: Lyxumia is started at a dose of 10 micrograms once a day which is increased to 20 micrograms once a day after 14 days.
Croatian: Terapija lijekom Lyxumia počinje s dozom od 10 mikrograma jednom na dan što se povećava na 20 mikrograma jednom na dan nakon 14 dana.
English: For more information about treatment with Lyxumia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Lyxumia pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: If the patient is already taking a sulphonylurea (another diabetes medicine) or basal insulin, the doctor may need to reduce the dose of the sulphonylurea or basal insulin because there is a risk of hypoglycaemia (low blood sugar levels).
Croatian: Ako bolesnik već uzima sulfonilureju (drugi lijek protiv dijabetesa) ili bazalni inzulin, liječnik će možda morati smanjiti dozu sulfonilureje ili bazalnog inzulina jer postoji rizik od hipoglikemije (niskih razina šećera u krvi).
English: Lyxumia was more effective than placebo at controlling blood glucose.
Croatian: Lyxumia se pokazala djelotvornijom od placeba prilikom kontrole glukoze u krvi.
English: All of the studies measured the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Croatian: Sva su ispitivanja mjerila promjenu u razini glikoliziranog hemoglobina (HbA1c) što je postotak hemoglobina u krvi koji veže glukozu.
English: A risk management plan has been developed to ensure that Lyxumia is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Lyxumia.
English: The active substance in Lyxumia, lixisenatide, is a ‘GLP-1 receptor agonist'.
Croatian: Djelatna tvar u lijeku Lyxumia, liksisenatid je „agonist receptora GLP-1”.
English: It works by attaching to glucagon-like peptide 1 (GLP-1) receptors that are found on the surface of the cells in the pancreas and that cause the production of insulin by the pancreas.
Croatian: Djeluje vezivanjem na receptore glukagonu sličnog peptida 1 (GLP-1) koji se nalaze na površini stanica gušterače i koji uzrokuju stvaranje inzulina u gušterači.
English: What is the risk associated with Lyxumia?
Croatian: Koji su rizici povezani s lijekom Lyxumia?
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Croatian: Dijabetes tipa 2 je bolest kod koje gušterača ne proizvodi dovoljno inzulina kako bi kontrolirala razinu glukoze u krvi ili kada tijelo nije u stanju učinkovito koristiti inzulin.
English: The most common side effects with Lyxumia (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea and headache.
Croatian: Najčešće nuspojave lijeka Lyxumia (mogu se javiti kod više od 1 na 10 bolesnika) bile su mučnina, povraćanje, proljev i glavobolja.
English: The study comparing Lyxumia with exenatide (added to metformin) showed reduced HbA1c levels by 0.79% after 24 weeks treatment with Lyxumia compared to 0.96% with exenatide twice daily.
Croatian: Ispitivanje koje je uspoređivalo lijek Lyxumia s eksenatidom (koji je dodan metforminu) pokazalo je smanjene razine HbA1c za 0,79 % nakon 24-tjedne terapije Lyxumiom u usporedbi s 0,96 % s eksenatidom dva puta na dan.
English: Lyxumia should not be given with a combination of both, basal insulin and a sulphonylurea.
Croatian: Lijek Lyxumia ne smije se davati u kombinaciju s oba lijeka, bazalnim inzulinom i sulfonilurejom.
English: The CHMP concluded that Lyxumia was shown to be effective at lowering blood glucose levels in patients with type 2 diabetes, when given alone or in combination with other diabetes medicines.
Croatian: CHMP je zaključio da se pokazalo da je lijek Lyxumia učinkovit u snižavanju razina glukoze u krvi u bolesnika s dijabetesom tipa 2 kada se daje sam ili u kombinaciji s drugim lijekovima protiv dijabetesa.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Lyxumia, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Lyxumia nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: When used on its own, Lyxumia reduced Hb1Ac levels by 0.6% more than placebo.
Croatian: Kada se koristila nasamo, Lyxumia je reducirala razine Hb1Ac za 0,6 % više od placeba.
English: HbA1c gives an indication of how well the blood glucose is controlled.
Croatian: Razine HbA1c pokazuju kako se dobro kontrolira razina glukoze u krvi.
English: Why has Lyxumia been approved?
Croatian: Zašto je Lyxumia odobren?
English: Regarding its safety, most side effects are comparable to those of other similar diabetes medicines with side effects affecting the gut being the most common ones.
Croatian: Što se tiče sigurnosti, većina nuspojava usporediva s onima kod sličnih lijekova protiv dijabetesa dok su im najčešće nuspojave one koje zahvaćaju probavni sustav.
English: Six of the studies compared Lyxumia with placebo (a dummy treatment), used alone or when added to metformin, a sulphonylurea, basal insulin, or a combination of two of these medicines, in patients in whom previous treatment had failed.
Croatian: Šest ispitivanja uspoređivalo je Lyxumiu s placebom (prividnim liječenjem) koje se koristilo samo ili uz dodatak metformina, sulfonilureje, bazalnog inzulina ili kombinacije ova dva lijeka kod bolesnika kod kojih prethodno liječenje nije uspjelo.
English: Lyxumia is a diabetes medicine that contains the active substance lixisenatide.
Croatian: Lyxumia je lijek protiv dijabetesa koji sadrži djelatnu tvar liksisenatid.
English: HbA1c levels were measured after 12 weeks when Lyxumia was used alone and after 24 weeks when it was used in combination with other diabetes medicines.
Croatian: Razine HbA1c mjerene su 12 tjedana nakon što se Lyxumia primjenjivala sama te 24 tjedna nakon što je primjenjivana u kombinaciji s drugim antidijabeticima.
English: Lyxumia is used in adults who have type 2 diabetes to control their blood glucose (sugar) level.
Croatian: Lyxumia se koristi kod odraslih osoba s dijabetesom mellitusom tipa 2 za kontrolu razine njihove glukoze u krvi (šećera).
English: It is used together with diabetes medicines taken by mouth and/or basal insulin (long-acting insulin) in patients whose blood glucose levels are not adequately controlled by these medicines together with diet and exercise.
Croatian: Koristi se skupa s lijekovima protiv dijabetesa koji se uzimaju kroz usta i/ili bazalnim inzulinom (inzulinom dugog djelovanja) kod bolesnika čije razine glukoze u krvi nisu kontrolirane na odgovarajući način ovim lijekovima skupa s dijetom i tjelovježbom.
English: What is Lyxumia?
Croatian: Što je Lyxumia?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lyxumia.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek Lyxumia da bi preporučio njegovo odobrenje za stavljanje na tržište te uvjete za njegovu primjenu.
English: When used in combination with other diabetes medicines, Lyxumia reduced Hb1Ac levels by 0.4 up to 0.9% more than placebo.
Croatian: Kada se koristila u kombinaciji s drugim lijekovima protiv dijabetesa, Lyxumia je smanjila razine Hb1Ac za 0,4 do 0,9 % više nego placebo.
English: When used together with a sulphonylurea or basal insulin, the most common side effect (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Croatian: Kada se koristi skupa sa sulfonilurejom ili bazalnim inzulinom najčešća nuspojava (može se javiti kod više od 1 na 10 bolesnika) bila je hipoglikemija (niske razine glukoze u krvi).
English: In one study, Lyxumia was compared with another diabetes medicine called exenatide when added to metformin in patients whose blood sugar levels were not adequately controlled by metformin.
Croatian: U jednom je ispitivanju Lyxumia uspoređena s drugim lijekom protiv dijabetesa zvanim eksenatid kad se dodavao metforminu kod bolesnika čije razine glukoze u krvi nisu bile na odgovarajući način kontrolirane metforminom.
English: This causes the release of insulin and helps to reduce blood glucose levels and control type 2 diabetes.
Croatian: To uzrokuje otpuštanje inzulina, pomaže u smanjenju razine glukoze u krvi te kontrolira dijabetes tipa 2.
English: The CHMP concluded that the benefits of Lyxumia outweigh its risks and recommended that it be granted marketing authorisation.
Croatian: Odbor za lijekove za primjenu kod ljudi (CHMP) odlučio je da koristi od lijeka Lyxumia nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za stavljanje u promet.
English: For the full list of all side effects and restrictions with Lyxumia, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Lyxumia, potražite u uputi o lijeku.
English: What benefit has Lyxumia shown during the studies?
Croatian: Koje su koristi lijeka Lyxumia utvrđene u ispitivanjima?
English: What is Lyxumia used for?
Croatian: Za što se Lyxumia koristi?
English: In addition, beneficial weight loss was seen in patients treated with Lyxumia.
Croatian: Pored toga, kod bolesnika liječenih lijekom Lyxumia uočen je koristan gubitak tjelesne težine.
English: How is Lyxumia used?
Croatian: Kako se koristi Lyxumia?
English: How does Lyxumia work?
Croatian: Kako djeluje Lyxumia?
English: How has Lyxumia been studied?
Croatian: Kako je Lyxumia ispitivana?
English: QUALIGEN, SL
Croatian: Španjolska QUALIGEN, SL
English: Baclofeno Generis baclofen
Croatian: Baclofeno Generis baklofen
English: Hexal AG, Germany
Croatian: Hexal AG, Njemačka
English: Laboratórios Basi - Indústria Farm
Croatian: Laboratórios BasiIndústria Farm
English: Annex Ib: Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation
Croatian: Prilog I.b: Lijekovi za koje se preporučuje obustava odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje lijeka u promet koji ne udovoljavaju kriterijima za izdavanje odobrenja
English: BRADEX AEBE DUTASTERIDE/BRADEX
Croatian: BRADEX AEBE DUTASTERIDE/BRADEX dutasterid
English: Annex Ia: Medicinal products recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à-vis the EU reference medicinal product has been established
Croatian: Prilog I.a: Lijekovi za koje se preporučuje zadržavanje odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje lijeka u promet za koje je utvrđena bioekvivalencija u odnosu na referentni lijek odobren u EU-u
English: tianeptine
Croatian: tianeptin
English: Corporation Orion Pharma, Finland
Croatian: Orion Corporation Orion Pharma, Finska
English: Carbocisteine 375 mg Capsules, Hard carbocisteine
Croatian: Carbocisteine 375 mg Capsules, Hard karbocistein
English: Belfada aripiprazole
Croatian: Belfada aripiprazol
English: Sandoz A/S, Denmark
Croatian: Sandoz A/S, Danska
English: Belgium Sandoz n.v./s.a.
Croatian: Sandoz n.v./s.a.
English: Prednisolon Alternova prednisolone
Croatian: Prednisolon Alternova prednisolon
English: United Kingdom Lupin (Europe) Limited
Croatian: Lupin (Europe) Limited
English: The Netherlands Sandoz B.V.
Croatian: Nizozemska Sandoz B.V.
English: LABORATORIOS COMBIX, SLU
Croatian: Španjolska LABORATORIOS COMBIX, SLU
English: Loperamid Apofri loperamide
Croatian: Loperamid Apofri loperamid
English: United Kingdom Medreich PLC
Croatian: Medreich PLC
English: Metoklopramid Alternova metoclopramide
Croatian: Metoklopramid Alternova metoklopramid
English: Loperamid Orifarm loperamide
Croatian: Loperamid Orifarm loperamid
English: United Kingdom Strides Arcolab International
Croatian: Španjolska Strides Arcolab International
English: Alternova A/S Hydrokortison Alternova hydrocortisone
Croatian: Alternova A/S Hydrokortison Alternova hidrokortizon
English: Bendro-flumetiazid Alternova bendro-flumethiazide 2.5 mg Tablet
Croatian: Bendro-flumetiazid Alternova bendroflumetiazid 2,5 mg tableta
English: Alternova A/S Baklofen Alternova baclofen
Croatian: Alternova A/S Baklofen Alternova baklofen
English: ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ.
Croatian: ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. PHARMAZAC AE
English: Sodium Cromoglicate 100mg hard Capsules sodium cromoglicate 100 mg Capsule, hard Oral use
Croatian: Sodium Cromoglicate 100mg hard Capsules natrijev kromoglikat 100 mg kapsula, tvrda peroralna primjena
English: Alternova A/S Etodolac Alternova etodolac
Croatian: Alternova A/S Etodolac Alternova etodolak
English: Clindamycin Alternova clindamycin
Croatian: Clindamycin Alternova klindamicin
English: AUROVITAS SPAIN, SAU
Croatian: Španjolska AUROVITAS SPAIN, SAU
English: ethinylestradiol / levonorgestrel
Croatian: etinilestradiol/levonor gestrel
English: hydrocortisone
Croatian: hidrokortizon
English: FarmozSociedade Técnico Medicinal, S.A.
Croatian: Farmoz - Sociedade Técnico Medicinal, S.A.
English: LABORATORIOS AUROBINDO, SLU
Croatian: Španjolska LABORATORIOS AUROBINDO, SLU
English: Morysa memantine
Croatian: Morysa memantin
English: SANDOZ FARMACEUTICA, SA
Croatian: Španjolska SANDOZ FARMACEUTICA, SA
English: Maexeni 30 0,03 mg/0,15 mg Filmtabletten ethinylestradiol / levonorgestrel mg/0.15 mg neuraxpharm Arzneimittel GmbH
Croatian: Maexeni 30 0,03 mg/0,15 mg Filmtabletten etinilestradiol/levonor gestrel mg/0,15 mg neuraxpharm Arzneimittel GmbH
English: United Kingdom Dawa Limited
Croatian: Dawa Limited
English: Memantine Pharmascope memantine
Croatian: Memantine Pharmascope memantin
English: 1 A Pharma GmbH, Germany
Croatian: 1 A Pharma GmbH, Njemačka
English: LARCIA 125 MIKROGRAMŮ/30 MIKROGRAMŮ
Croatian: MIKROGRAMŮ/30 MIKROGRAMŮ
English: United Kingdom Kinedexe UK Limited (previously
Croatian: Kinedexe UK Limited (prethodno NRIM Limited)
English: Omega 3-acid-ethyl esters 1000mg soft capsules omega-3-acid-ethyl esters 90
Croatian: Omega 3-acid-ethyl esters 1000mg soft capsules etilni[90]esteri omega-3 kiselina
English: Corporation, Finland
Croatian: Orion Corporation, Finska
English: dutasteride
Croatian: dutasterid
English: voriconazol
Croatian: vorikonazol
English: Speciality Pharma Limited
Croatian: Generic Speciality Pharma Limited
English: PUREN Pharma GmbH & Co. KG
Croatian: PUREN Pharma GmbH & Co.
English: United Kingdom Milpharm Limited
Croatian: Milpharm Limited
English: Naproxen Orion
Croatian: Naproxen Orion naproksen
English: Medreich PLC Gliclazide 40 mg tablets gliclazide
Croatian: Medreich PLC Gliclazide 40 mg tablets gliklazid
English: memantine
Croatian: memantin
English: Biogaran hydroxyzine BIOGARAN hydroxyzine
Croatian: Biogaran hydroxyzine BIOGARAN hidroksizin
English: Beta-histina Bluefish
Croatian: Beta-histina Bluefish betahistin
English: loperamide
Croatian: loperamid
English: Gliclazide 80mg Tablets gliclazide
Croatian: Gliclazide 80mg Tablets gliklazid
English: Loperamid Evolan loperamide
Croatian: Evolan Pharma AB Loperamid Evolan loperamid
English: Beta- histina Bluefish betahistine dihydrochloride
Croatian: Beta- histina Bluefish betahistin dihidroklorid
English: Gliclazide 40mg Tablets gliclazide
Croatian: Gliclazide 40mg Tablets gliklazid
English: The Netherlands Aurobindo Pharma B.V.
Croatian: Nizozemska Aurobindo Pharma B.V.
English: Hydroxyzine hydrochloride 25mg film-coated tablets hydroxyzine hydrochloride
Croatian: Hydroxyzine hydrochloride 25mg film-coated tablets hidroksizin hidroklorid 25 mg filmom obložena tableta